530 related articles for article (PubMed ID: 33776489)
1. Advances in Our Understanding of the Molecular Mechanisms of Action of Cisplatin in Cancer Therapy.
Tchounwou PB; Dasari S; Noubissi FK; Ray P; Kumar S
J Exp Pharmacol; 2021; 13():303-328. PubMed ID: 33776489
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-Based Chemotherapy of Human Cancers.
Brown A; Kumar S; Tchounwou PB
J Cancer Sci Ther; 2019; 11(4):. PubMed ID: 32148661
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin in cancer therapy: molecular mechanisms of action.
Dasari S; Tchounwou PB
Eur J Pharmacol; 2014 Oct; 740():364-78. PubMed ID: 25058905
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review).
Wang G; Reed E; Li QQ
Oncol Rep; 2004 Nov; 12(5):955-65. PubMed ID: 15492778
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin: The first metal based anticancer drug.
Ghosh S
Bioorg Chem; 2019 Jul; 88():102925. PubMed ID: 31003078
[TBL] [Abstract][Full Text] [Related]
7. Platinum Complexes in Colorectal Cancer and Other Solid Tumors.
Köberle B; Schoch S
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922989
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of cisplatin resistance.
Galluzzi L; Senovilla L; Vitale I; Michels J; Martins I; Kepp O; Castedo M; Kroemer G
Oncogene; 2012 Apr; 31(15):1869-83. PubMed ID: 21892204
[TBL] [Abstract][Full Text] [Related]
9. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells.
Kumar S; Tchounwou PB
Oncotarget; 2015 Dec; 6(38):40734-46. PubMed ID: 26486083
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Zanjirband M; Edmondson RJ; Lunec J
Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.
Florea AM; Büsselberg D
Cancers (Basel); 2011 Mar; 3(1):1351-71. PubMed ID: 24212665
[TBL] [Abstract][Full Text] [Related]
13. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of resistance to cisplatin.
Kartalou M; Essigmann JM
Mutat Res; 2001 Jul; 478(1-2):23-43. PubMed ID: 11406167
[TBL] [Abstract][Full Text] [Related]
15. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
Ayyagari VN; Hsieh TJ; Diaz-Sylvester PL; Brard L
BMC Cancer; 2017 Jan; 17(1):49. PubMed ID: 28086831
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin resistance and oncogenes--a review.
Dempke W; Voigt W; Grothey A; Hill BT; Schmoll HJ
Anticancer Drugs; 2000 Apr; 11(4):225-36. PubMed ID: 10898536
[TBL] [Abstract][Full Text] [Related]
18. Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells.
Tu Y; Kim E; Gao Y; Rankin GO; Li B; Chen YC
Int J Oncol; 2016 Jun; 48(6):2657-65. PubMed ID: 27082635
[TBL] [Abstract][Full Text] [Related]
19. Promotion of p53 expression and reactive oxidative stress production is involved in zerumbone-induced cisplatin sensitization of non-small cell lung cancer cells.
Hu Z; Zeng Q; Zhang B; Liu H; Wang W
Biochimie; 2014 Dec; 107 Pt B():257-62. PubMed ID: 25220870
[TBL] [Abstract][Full Text] [Related]
20. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
